Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.

Conference item

BACKGROUND: Two parallel studies evaluated safety and immunogenicity of a prophylactic HIV-1 vaccine in 192 HIV-seronegative, low-risk volunteers. Modified vaccinia virus Ankara (MVA) and plasmid DNA (pTHr) expressed HIV-1 clade A gag p24 and p17 fused to a string of 25 overlapping CD8+ T cell epitopes (HIVA). METHODS: These studies compared intramuscular, subcutaneous, and intradermal MVA at dosage levels ranging from 5x10(6)-2.5x10(8) pfu. In Study IAVI-010, DNA vaccine was given as a prime...

Expand abstract

Authors: Peters, B; Jaoko, W; Vardas, E; Panayotakopoulos, G; Fast, P

• Publication status: Published
• Host title: Vaccine
• Volume: 25
• Issue: 11
• Pages: 2120-2127
• Publication date: 2007-03-01
• Event location: Netherlands
• DOI: 10.1016/j.vaccine.2006.11.016
• EISSN: 1873-2518
• ISSN: 0264-410X
• Keywords: Adolescent; Injections, Subcutaneous; Vaccines, DNA; Humans; Interferon-gamma; Injections, Intramuscular; Adult; Immunization, Secondary; Leukocytes, Mononuclear; Female; Male; Injections, Intradermal; Epitopes, T-Lymphocyte; HIV-1; AIDS Vaccines; Middle Aged; Vaccination